Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
miR-101-2 precursor microRNA (miR-101-2)
- Target
- miR-101-2
- Molecular classification
- microRNA, non-coding RNA, gene regulator
01
Overview
miR-101-2 precursor microRNA is a small, non-coding RNA located on chromosome 9p24.1; together with miR-101-1, it encodes miR-101, a highly conserved tumor suppressor implicated in multiple cancers and other diseases. It regulates gene expression post-transcriptionally by directing RISC-mediated mRNA silencing or degradation. miR-101-2 is involved in apoptosis, cell cycle, migration, and autophagy, and serves as a biomarker for cancer prognosis and patient stratification. Both its dysregulation and potential for therapeutic targeting are active areas of research.
- Other names
- miR-101hsa-mir-101-2 (human microRNA 101-2 precursor)MIR101-2 (gene symbol)microRNA 101miR-101 precursor
02
Mechanism of action
Gene silencing (via RISC complex), mRNA degradation, and translational inhibition. Therapeutics would act by restoring or inhibiting miR-101 function, affecting its downstream targets such as EZH2, SOX9, and RAB5A.
03
Biological functions
Gene expression regulation (post-transcriptional silencing)ApoptosisCell proliferationCell migration/invasionAutophagy inhibitionTumor suppression
04
Disease associations
Cancer (as a tumor suppressor; down-regulated in various cancers)Fibrosis (pulmonary, hepatic)Cardiovascular diseaseNeurodegenerative disease (potential biomarker in Parkinson’s disease; see downregulation in patients)Other (angiogenesis, metastasis)
05
Safety considerations
Off-target gene regulationPotential for unwanted activation/suppression of pathways important for normal tissue functionDelivery barriers for miRNA-based therapies
06
Biomarkers
miR-101 (including the miR-101-2 precursor) is a biomarker for cancer diagnosis, prognosis, and therapeutic response. Its downregulation is correlated with tumor size, grade, and poor survival in cancers such as gastric, lung, breast, oral squamous cell carcinoma
Beyond the preview
Go deeper on miR-101-2 precursor microRNA (miR-101-2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-101-2 precursor microRNA (miR-101-2).